Zymeworks BC Inc (NASDAQ: ZYME) is -14.28% lower on its value in year-to-date trading and has touched a low of $7.97 and a high of $17.70 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ZYME stock was last observed hovering at around $12.28 in the last trading session, with the day’s gains setting it 0.27%.
Currently trading at $12.55, the stock is -5.67% and -9.94% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.95 million and changing 2.20% at the moment leaves the stock 1.69% off its SMA200. ZYME registered 13.57% gain for a year compared to 6-month gain of 4.37%. The firm has a 50-day simple moving average (SMA 50) of $13.9356 and a 200-day simple moving average (SMA200) of $12.341375.
The stock witnessed a -5.28% loss in the last 1 month and extending the period to 3 months gives it a -4.49%, and is 3.46% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.98% over the week and 5.58% over the month.
Zymeworks BC Inc (ZYME) has around 286 employees, a market worth around $880.35M and $76.30M in sales. Profit margin for the company is -160.80%. Distance from 52-week low is 57.47% and -29.10% from its 52-week high. The company has generated returns on investments over the last 12 months (-34.61%).
The EPS is expected to shrink by -5.07% this year
246.0 institutions hold shares in Zymeworks BC Inc (ZYME), with institutional investors hold 99.39% of the company’s shares. The shares outstanding are 68.96M, and float is at 67.30M with Short Float at 5.89%. Institutions hold 99.31% of the Float.
Zymeworks BC Inc (ZYME) Insider Activity
The most recent transaction is an insider purchase by EcoR1 Capital, LLC, the company’s Director. SEC filings show that EcoR1 Capital, LLC bought 468,356 shares of the company’s common stock on Mar 13 ’25 at a price of $12.48 per share for a total of $5.85 million. Following the purchase, the insider now owns 16.8 million shares.
Zymeworks BC Inc disclosed in a document filed with the SEC on Mar 11 ’25 that EcoR1 Capital, LLC (Director) bought a total of 320,690 shares of the company’s common stock. The trade occurred on Mar 11 ’25 and was made at $11.49 per share for $3.69 million. Following the transaction, the insider now directly holds 16.04 million shares of the ZYME stock.
Still, SEC filings show that on Mar 12 ’25, EcoR1 Capital, LLC (Director) acquired 292,934 shares at an average price of $12.25 for $3.59 million. The insider now directly holds 16,333,785 shares of Zymeworks BC Inc (ZYME).
